Treatment of patients with R AS-mutated colorectal cancer with lung metastases

Objective: to present and analyze the clinical treatment outcomes of patients with RAS-mutated metastatic colorectal cancer based on two case reports, assessing the efficacy of systemic therapy regimens, and demonstrating factors influencing treatment strategy and tumor response. These cases demonstrate the need for new markers and a personalized approach to therapy in patients with colorectal cancer. These observations were compared with current literature data, demonstrating the practical value of an individualized approach to treating patients with RAS-mutated metastatic colorectal cancer.

1. Sung H., Ferlay J., Siegel R.L., et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71(3):209–249. https://doi.org/10.3322/caac.21660

2. Cañellas-Socias A., Sancho E., Batlle E. Mechanisms of metastatic colorectal cancer. Nat Rev Gastroenterol Hepatol 2024;21(9):609-625. https://doi.org/10.1038/s41575-024-00934-z

3. American Cancer Society: A bout Colorectal Cancer (2022). [cited 4 November 2022]. Available f rom: https://www. cancer.org/cancer/colon-rectal-cancer/about.html/

4. Colon and Rectum SEER 5-Year Relative Survival Rates, 2011–2017. In: SEER*Explorer: An interactive website for SEER cancer statistics. Surveillance, Epidemiology, and End Results Program, National Cancer Institute. Available at: https://seer.cancer.gov/explorer/application.html?site=20&data_type=4&graph_type=5&compareBy=stage&chk_stage_104=104&chk_stage_105=105&chk_stage_106=106&chk_stage_107=107&series=9&sex=1&race=1&age_range=1&advopt_precision=1&advopt_show_ci=on#tableWrap

5. The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487(7407):330–337. https://doi.org/10.1038/nature11252

6. Feng J., Hu Z., Xia X., et al. Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer. Oncogene 2023;42(20), 1620–1633. https://doi.org/10.1038/s41388-023-02676-9

7. Pereira A.A., Rego J.F., Morris V., et al. Association between KRAS mutation and lung metastasis in advanced colorectal cancer. Br J Cancer 2015;112(3):424–428. https://doi.org/10.1038/bjc.2014.619

8. Yaeger R., Weiss J., Pelster M.S., et al. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C. N Engl J Med 2023;388(1):44-54. https://doi.org/10.1056/NEJMoa2212419

9. Pellatt A.J., Bhamidipati D., Subbiah V. Ready, Set, Go: Setting Off on the Mission to Target KRAS in Colorectal Cancer. JCO Oncol Pract 2024;20(10):1289-1292. https://doi.org/10.1200/OP.24.00295

10. Kawazoe A., Xu R.H., García-Alfonso P., et al. Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer: final analysis of the randomized, open-label, phase III LEAP-017 Study. J Clin Oncol 2024;42(24):2918-2927. https://doi.org/10.1200/JCO.23.02736

11. Margalit O., Shacham-Shmueli E., Lawrence Y.R., et al. Lung metastasis predicts better prognosis in metastatic colorectal cancer with mutated KRAS. Clin Colorectal Сancer 2019;18(3):e300–e307. https://doi.org/10.1016/j.clcc.2019.06.001

12. NCCN Clinical Practice Guideline for Colon Cancer. Version 3.2025. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf

13. Petrella F., Danuzzo F., Sibilia M.C., et al. Colorectal Cancer Pulmonary Metastasectomy: When, Why and How. Cancers (Basel.) 2024;16(7):1408. https://doi.org/10.3390/cancers16071408

14. Cremolini C., Loupakis F., Antoniotti C., et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 2015;16(13):1306-1315. https://doi.org/10.1016/S1470-2045(15)00122-9

15. Rossini D., Lonardi S., Antoniotti C., et al. Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO. Br J Cancer 2021;124(1):183–190. https://doi.org/10.1038/s41416-020-01089-9

16. Stahler A., Heinemann V., Ricard I., et al. Current treatment options in RAS mutant metastatic colorectal cancer patients: a meta-analysis of 14 randomized phase III trials. J Cancer Res Clin Oncol 2020;146(8):2077–2087. https://doi.org/10.1007/s00432-020-03290-y

17. Osterlund P., Salminen T., Soveri L .M., et al. Repeated centralized multidisciplinary team assessment of resectability, clinical behavior, and outcomes in 1086 Finnish metastatic colorectal cancer patients (RAXO): A nationwide prospective intervention study. Lancet Reg Health Eur 2021;3(6):100049. https://doi.org/10.1016/j.lanepe.2021.100049

18. Primrose J., Falk S., Finch-Jones M., et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial [published correction appears in Lancet Oncol 2014;15(7):e253]. Lancet Oncol 2014;15(6):601-611. https://doi.org/10.1016/S1470-2045(14)70105-6

19. Fedyanin M., Polyanskaya E., Pokataev I., et al. Use of the FOLFOXiRi combination in patients with colon cancer and isolated unresectable liver metastases: a prospective, non-randomized, single-center phase II study. Surgery and oncology 2019;9(4):21-31. (in Russ.). https://doi.org/10.17650/2686-9594-2019-9-4-21-31

20. Cervantes A., Adam R., Roselló S., et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023;34(1):10-32. https://doi.org/10.1016/j.annonc.2022.10.003

21. Fedyanin M.Yu., Gladkov O.A., Gordeev S.S., et al. Cancer of the colon, rectosigmoid junction and rectum. Malignant tumors 2024;14(3s2-1):263-322. (in Russ.). https://doi.org/10.18027/2224-5057-2024-14-3s2-1.1-14

22. Scheer M.G., Sloots C.E., van der Wilt G.J., Ruers T.J. Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases. Ann Oncol 2008;19(11):1829-1835. https://doi.org/10.1093/annonc/mdn398

23. Cirocchi R ., Trastulli S ., A braha I ., et a l. Non-resection versus resection for a n a symptomatic p rimary t umour i n patients with unresectable stage IV colorectal cancer. Cochrane Database Syst Rev 2012;2012(8):CD008997. https://doi.org/10.1002/14651858.CD008997.pub2